X
Xinghao Ai
Researcher at Shanghai Jiao Tong University
Publications - 7
Citations - 97
Xinghao Ai is an academic researcher from Shanghai Jiao Tong University. The author has contributed to research in topics: Lung cancer & Anaplastic lymphoma kinase. The author has an hindex of 4, co-authored 7 publications receiving 45 citations.
Papers
More filters
Journal ArticleDOI
Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study
Chang Lu,Chang Lu,Xiao-Rong Dong,Jun Zhao,Xu-Chao Zhang,Hua-Jun Chen,Qing Zhou,Hai-Yan Tu,Xinghao Ai,Xiao-Feng Chen,Gai-Li An,Jun Bai,Jin-Lu Shan,Yina Wang,Shuanying Yang,Xiang Liu,Wu Zhuang,Hui-Ta Wu,Bo Zhu,Xuefeng Xia,Rongrong Chen,Dejian Gu,Huamin Xu,Yi-Long Wu,Yi-Long Wu,Jin-Ji Yang,Jin-Ji Yang +26 more
TL;DR: Patients with concurrent TP53 mutation or high peripheral blood TCR repertoire diversity have relatively inferior overall survival in this series, and outcomes with traditional systemic therapies in general are suboptimal.
Journal ArticleDOI
Clonal architecture of EGFR mutation predicts the efficacy of EGFR-Tyrosine Kinase Inhibitors in advanced NSCLC: a prospective multicenter study (NCT03059641).
Xinghao Ai,Jiuwei Cui,Jiexia Zhang,Rongrong Chen,Wen Lin,Congying Xie,Anwen Liu,Junping Zhang,Weihua Yang,X. Hu,Qiong Zhao,Chuangzhou Rao,Yuan-Sheng Zang,Ruiling Ning,Pansong Li,Lianpeng Chang,Xin Yi,Shun Lu +17 more
TL;DR: Paired tissue and ctDNA could be analyzed for clonal architecture in advanced cancer and EGFR mutations do not always make up a dominant clone in advanced NSCLC, which was associated with the efficacy of EGFR-TKIs inNSCLC.
Journal ArticleDOI
Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient
TL;DR: This case further illustrates the importance of comprehensive genomic profiling of resistant tumors for tailoring treatment decisions after disease progression on crizotinib in ALK + NSCLC in the era of rapidly developing new-generation ALK inhibitors and other therapeutic strategies.
Journal ArticleDOI
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study
Xinghao Ai,Yueyin Pan,Jianhua Shi,Nong Yang,Chunling Liu,Jianying Zhou,Xiaodong Zhang,Xiaorong Dong,Jianxing He,Xiao-Ling Li,Gongyan Chen,Xingya Li,Helong Zhang,Wangjun Liao,Yiping Zhang,Zhiyong Ma,Liyan Jiang,Jiuwei Cui,Chunhong Hu,Wei Wang,Cheng Huang,Jun Zhao,Cuimin Ding,X. Hu,Kai Wang,Beili Gao,Yong Song,Xiaoqing Liu,Jianping Xiong,Anwen Liu,Junling Li,Zhe Liu,Yinyin Li,Mengzhao Wang,Biao Zhang,Dan Zhang,Shun Lu +36 more
TL;DR: ZL-2306-005 as discussed by the authors is a randomized, double-blind, multicenter phase 3 study evaluating the efficacy and safety of niraparib, a poly(adenosine diphosphate-ribose) polymerase inhibitor, as first-line maintenance therapy in Chinese patients with extensive-stage SCLC (ES-SCLC).
Journal ArticleDOI
Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib.
Bo Yuan,Jun Zhao,Chengzhi Zhou,Xiumei Wang,Bo Zhu,Minglei Zhuo,Xilin Dong,Jiemei Feng,Cuihua Yi,Yunpeng Yang,Hua Zhang,Wangyan Zhou,Zhengtang Chen,Sheng Yang,Xinghao Ai,Kehe Chen,Xuefan Cui,Difa Liu,Chunmei Shi,Wei Wu,Yanjun Zhang,Lianpeng Chang,Jin Li,Rongrong Chen,Shuanying Yang +24 more
TL;DR: The data revealed co-occurring TP53 represent an unfavorable prognosis of patients with ERBB2ex20ins, emphasizing the more valuable role of the co-mutation patterns than insertion-site subtypes in predicting prog outlook of this group of patients.